Tigermed and WuXi Biologics took part in the biopharmaceutical company's series D round, which will accelerate the development of its immuno-oncology drug candidates.
Adlai Nortye, a China-based developer of cancer treatments, has raised $100m in a series D round co-led by Tigermed and investment firm CMG-SDIC Capital, DealStreetAsia reported on Tuesday.
The round was also backed by Legend Star, a corporate venture capital subsidiary of conglomerate Legend Holdings, as well as contract pharmaceutical manufacturer WuXi Biologics’ industry fund.
Adlai Nortye is working on immuno-oncology treatments for cancer, and its pipeline of clinical-stage drug candidates includes Reolysin, an intravenously delivered immuno-oncolytic virus (IOV) being…
